A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Phase 2 Recruiting
62 enrolled
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
25 enrolled
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/2 Recruiting
27 enrolled
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Phase 2 Recruiting
60 enrolled
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Phase 2 Recruiting
60 enrolled
MK-3543-017
Phase 3 Recruiting
400 enrolled
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Phase 2 Recruiting
30 enrolled
GIV-IN-PV
Phase 3 Recruiting
220 enrolled
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Recruiting
5,000 enrolled
ROPE
Recruiting
200 enrolled
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Phase 2 Recruiting
60 enrolled
CONT-LOW-PV
Recruiting
36 enrolled
ET2PV
Recruiting
678 enrolled
TREATMORE
Phase 2 Recruiting
54 enrolled
PHEMOP
Phase NA Recruiting
70 enrolled
POLYVISCO
Recruiting
160 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 Recruiting
108 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Phase 1 Recruiting
108 enrolled
MITHRIDATE
Phase 3 Recruiting
586 enrolled
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Phase 3 Recruiting
67 enrolled
Myeloproliferative Neoplasms (MPNs) Patient Registry
Recruiting
5,000 enrolled
OBENE
Recruiting
1,000 enrolled
PV
Phase 2 Recruiting
94 enrolled
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 Recruiting
24 enrolled
Asian Myeloproliferative Neoplasm (MPN) Registry
Recruiting
1,000 enrolled